HEPATOCELLULAR CARCINOMA (HCC)

Exploring dysfunctional pathways, mechanisms, and biomarkers
in HCC to discover new insights into the progression of the disease.

~90%

of cases of liver cancer, making it the most common form1

6th

most common cancer worldwide2

Abbvie Science

4th

leading cause of cancer-related death globally2

INCIDENCE & MORTALITY

Abbvie Science
  • Incidence is 2 to 4 times greater in men than women, which stems from behavioral and metabolic factors.3
  • The median age at diagnosis is 61 years in men and 68 years in women.4
  • 5-year relative survival rate is 21.6%5
    • Localized: 37.3%, regional: 14.3%, distant: 3.5%
  • Estimated new cases in the US in 2023: 41,210
  • Estimated deaths in the US in 2023: 29,380
  • Median overall survival for current standard of care in first line HCC is 19.2 months and ~8-11 months for second line and beyond.1

HCC is a heterogeneous disease, symptoms include increased clotting time, jaundice, encephalopathy, with many bodily processes affected and varying degrees of severity.6 Complications with underlying liver cirrhosis make HCC difficult to diagnose. 

HCC is a heterogeneous disease, symptoms include increased clotting time, jaundice, encephalopathy, with many bodily processes affected and varying degrees of severity.6 Complications with underlying liver cirrhosis make HCC difficult to diagnose. 

HCC is a heterogeneous disease, symptoms include increased clotting time, jaundice, encephalopathy, with many bodily processes affected and varying degrees of severity.6 Complications with underlying liver cirrhosis make HCC difficult to diagnose. 

HCC is a heterogeneous disease, symptoms include increased clotting time, jaundice, encephalopathy, with many bodily processes affected and varying degrees of severity.6 Complications with underlying liver cirrhosis make HCC difficult to diagnose. 

HCC is a heterogeneous disease, symptoms include increased clotting time, jaundice, encephalopathy, with many bodily processes affected and varying degrees of severity.6 Complications with underlying liver cirrhosis make HCC difficult to diagnose. 

Related Work in HCC

Learn More About Our Investigational Agents in HCC

Learn More About Our Clinical Research in HCC

Tumor Types
  1. HCC Overview and Risk Factor
  2. Sung H, et al. CA Cancer J Clin. 2021;71(3):209-249.
  3. HCC Gender Predisposition
  4. Diagnosis age
  5. Prognosis
  6. Alcohol and HCC
  7. Llovet JM, et al. Nat Rev Dis Primers. 2021;7:6
  8. Wong V, et al. J Hepatol. 2023;79:842-852
  9. National Comprehensive Cancer Network. Hepatocellular Carcinoma. NCCN Guidelines. v2.2023. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1514. Accessed March 2024
  10. Reig M, et al. J Hepatol. 2022;76(3):681-693.
  11. Child-Pugh Accessed March 2024.
  12. Coffin P, He A. Int J Mol Sci. 2023;24:13274. 2. Gorji L, et al. Cancers. 2023;15:4221.
  13. AFP Prevalence
  14. Hepatocellular Carcinoma - My Cancer Genome
  15. Chen J, et al. Trends Mol Med. 2019;25(11):1010-1023.
  16. van Doorn DJ, et al. Pharmaceuticals (Basel). 2021;14(1):3

This AbbVie R&D oncology website focusing on science and cancer research is intended for the use of US Healthcare Professionals only.

This includes information that is important for scientific exchange. For a complete list of oncology pipeline molecules and more information, visit abbvie.com/science/pipeline.

Privacy Policy  |  Terms Of Use  |  Cookies Settings

Copyright © 2025 AbbVie Inc. North Chicago, Illinois, U.S.A. ABBV-US-01336-MC | V.5.0 | Approved 12/2025

Unless otherwise specified, all product names appearing on this Internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress on this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

AbbVie Science
footer logo